Trial Profile
A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 7652 (Primary)
- Indications Coronary disorders; Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- Acronyms EQUATOR
- Sponsors Genentech
- 01 Mar 2017 Results published in the American Journal of Cardiology
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.